Three-Pronged attack on advanced skin cancer tested in new trial
NCT ID NCT04091750
Summary
This study is testing whether adding a drug called cabozantinib to two existing immunotherapy drugs (nivolumab and ipilimumab) can better control advanced melanoma that cannot be removed by surgery. The main goal is to see if this combination helps patients live longer without their cancer getting worse. The treatment lasts up to two years, and researchers will closely monitor how well patients respond and manage any side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
Lombardi Comprehensive Cancer Center
Washington D.C., District of Columbia, 20007, United States
-
Medstar Franklin Square Medical Center, Harry and Jeanette Weinberg Cancer Institute
Baltimore, Maryland, 21237, United States
Conditions
Explore the condition pages connected to this study.